Prevalence of recurring symptoms after infection with Giardia lamblia in a non-endemic area.
OBJECTIVE
Investigation of the clinical course of infection with Giarda lamblia after a large outbreak in an area where Giardia is not endemic in humans.


METHODS
A cohort of patients from primary healthcare with clinically defined giardiasis was investigated by retrospectively analysing data from the patients' medical records.


METHODS
Urban primary healthcare setting in Bergen, Norway.


METHODS
From a population (n = 7100) assigned to two general practice clinics located in the outbreak area 134 patients met the inclusion criteria of at least one of the following: typical symptoms for at least one week, detection of Giarda lamblia in stool samples, or receiving a specific diagnosis. Of these, 119 gave consent to take part in the study.


METHODS
Proportion of patients with clinical giardiasis identified by detection of parasites in stool samples. Proportion of patients with prolonged disease and recurring symptoms.


RESULTS
A positive test for Giardia lamblia was found in 55% (66/119) of the patients. Specific treatment was given to 89 patients, and after treatment 36% (32/89) returned to their doctor because they experienced recurring symptoms. Compared with those not returning a significantly higher proportion of this group had seen their GP for other GI complaints in the previous two years.


CONCLUSIONS
Laboratory-based diagnosis missed a substantial number of patients falling sick with giardiasis during the outbreak. One-third of the patients experienced recurring symptoms after treatment, and there was an association between previous gastrointestinal complaints and recurrence of symptoms.
Wensaas
Knut-Arne
KA
Section for General Practice, Department of Public Health and Primary Health Care, University of Bergen, Kalfarveien 31, Bergen, Norway. awensaas@online.no
Langeland
Nina
N
Rortveit
Guri
G
D000293:Adolescent; D000328:Adult; D000368:Aged; D000818:Animals; D000981:Antiprotozoal Agents / Q000627:therapeutic use; D002675:Child, Preschool; D015331:Cohort Studies; D004196:Disease Outbreaks; D005243:Feces / Q000469:parasitology; D005260:Female; D016829:Giardia lamblia / Q000302:isolation & purification; D005873:Giardiasis / Q000188:drug therapy / Q000453:epidemiology*; D006801:Humans; D008297:Male; D008795:Metronidazole / Q000627:therapeutic use; D008875:Middle Aged; D009664:Norway / Q000453:epidemiology; D015995:Prevalence; D012008:Recurrence; D012189:Retrospective Studies; D055815:Young Adult
D000981:Antiprotozoal Agents; D008795:Metronidazole